The GTPBP1 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal cell population in which the GTPBP1 gene has been disrupted to create a functional knockout model. Unlike clonal cell lines, this product provides a heterogeneous pool of A-549 cells carrying diverse loss-of-function alleles, enabling robust population-level studies of GTPBP1-dependent processes without the confounding effects of single-cell clonal selection. The CRISPR/Cas9-mediated targeting introduces genetic lesions that abolish GTPBP1 protein expression, but the precise editing patterns??such as indel formation or exon deletion??are not characterized at the individual clone level. Researchers can leverage this polyclonal knockout system to assess gene function in a physiologically relevant, genetically diverse cellular background.
The host cell line A-549 is a well-established human lung adenocarcinoma epithelial model derived from a male patient with non-small cell lung cancer (NSCLC). These cells harbor an activating KRAS G12S mutation while retaining wild-type p53, representing a common genetic landscape in NSCLC. A-549 cells are extensively utilized to investigate oncogenic signaling, drug responses, and tumor biology due to their adherent epithelial morphology and capacity to recapitulate key features of lung adenocarcinoma. Their KRAS-driven proliferation and intact p53-mediated stress checkpoints make them particularly suitable for dissecting the interplay between translational control, cellular stress, and malignant phenotypes.
GTPBP1 encodes a translational GTPase that cooperates with eEF1A1 to regulate elongation during protein synthesis and directs stress granule assembly through direct binding to G3BP1. This gene is embedded in a signaling network where upstream regulators such as mTORC1, AMPK, and eIF2?? kinases converge to modulate its activity under nutrient availability and stress conditions. Downstream, GTPBP1 influences ribosomal protein S6, the transcription factor ATF4, and the core stress granule component G3BP1. Interacting factors including eEF1A1, G3BP1, RPLP0, RPS3, and PABPC1 further position GTPBP1 at the intersection of mRNA translation and cytoplasmic ribonucleoprotein dynamics. Mechanistically, GTPBP1 mediates adaptive protein synthesis adjustments via mTORC1-S6K-4E-BP1 and eIF2??-ATF4 axes, orchestrating cell survival during integrated stress responses.
In the A-549 cellular context, loss of GTPBP1 offers a powerful paradigm to examine how translational elongation and stress granule biology contribute to NSCLC pathology. The KRAS G12S mutation drives hyperactive mTORC1 signaling, which may intersect with GTPBP1-dependent ribosome function and stress adaptation. Knocking out GTPBP1 allows researchers to interrogate the gene??s role in sustaining proliferation under oncogenic stress, modulating sensitivity to nutrient deprivation, and regulating stress granule-mediated protection against chemotherapeutics. Moreover, the model can help elucidate whether GTPBP1 loss-of-function mirrors aspects of neurodegenerative conditions, given its established links to intellectual disability and ataxia, thereby extending its utility beyond cancer research.
This polyclonal knockout product is suited for diverse experimental workflows, including western blotting to verify GTPBP1 ablation, polysome profiling to quantify elongation rates, and immunofluorescence staining for stress granule markers under sodium arsenite or heat shock. Co-immunoprecipitation assays can map altered protein interaction networks involving eEF1A1 and G3BP1, while RNA-seq reveals transcriptome-wide consequences of GTPBP1 disruption. Apoptosis assays under endoplasmic reticulum stress further clarify its role in cell survival decisions. Applications encompass translation control in NSCLC, stress response dissection, drug target validation, and neurodegeneration modeling. For additional technical details, please contact Ascent Research.
